Toll Free: 1-888-928-9744

AbbVie Inc. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 187 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

AbbVie Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'AbbVie Inc. - Product Pipeline Review - 2014', provides an overview of the AbbVie Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AbbVie Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of AbbVie Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of AbbVie Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the AbbVie Inc.'s pipeline products

Reasons to buy

- Evaluate AbbVie Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of AbbVie Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the AbbVie Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of AbbVie Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of AbbVie Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of AbbVie Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
AbbVie Inc. Snapshot 6
AbbVie Inc. Overview 6
Key Information 6
Key Facts 6
AbbVie Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
AbbVie Inc. - Pipeline Review 13
Pipeline Products by Stage of Development 13
Pipeline Products - Monotherapy 14
Pipeline Products - Combination Treatment Modalities 15
Pipeline Products - Partnered Products 16
Pipeline Products - Out-Licensed Products 19
AbbVie Inc. - Pipeline Products Glance 21
AbbVie Inc. - Late Stage Pipeline Products 21
AbbVie Inc. - Clinical Stage Pipeline Products 25
AbbVie Inc. - Early Stage Pipeline Products 29
AbbVie Inc. - Drug Profiles 32
(carbidopa + levodopa) 32
ABT-450/r + ABT-267 + dasabuvir 34
adalimumab 37
ABT-450 39
ABT-450/r + ABT-267 41
ABT-450/r + ABT-267 + RBV 43
atrasentan hydrochloride 45
daclizumab 46
dasabuvir 49
elagolix sodium 51
elotuzumab 53
fluvoxamine maleate 55
ombitasvir 57
paricalcitol 59
veliparib 60
venetoclax + rituximab 62
ABT-122 64
ABT-126 65
ABT-436 67
ABT-493 68
ABT-493 + ABT-530 69
ABT-494 70
ABT-639 71
ABT-719 72
ABT-806 74
ABT-981 75
linifanib 76
navitoclax 78
venetoclax 80
ABT-414 82
ABBV-399 83
ABT-165 84
ABT-354 85
ABT-510 86
ABT-560 88
ABT-614 89
ABT-700 90
ABT-767 91
Antibody Drug Conjugate for Squamous Cell Tumor 92
ilorasertib 93
venetoclax + obinutuzumab 95
volociximab 96
A-1048400 100
A-1264087 101
A-431404 102
A-582941 103
A-705253 105
A-801195 106
A-836339 107
A-887755 108
A-889425 109
A-918446 110
ABT-487 111
ABT-731 112
ABT-737 113
ABT-898 115
Antibody Drug Conjugates for Cancer 116
SLV-330 117
SOL-1 118
AbbVie Inc. - Pipeline Analysis 119
AbbVie Inc. - Pipeline Products by Target 119
AbbVie Inc. - Pipeline Products by Route of Administration 124
AbbVie Inc. - Pipeline Products by Molecule Type 125
AbbVie Inc. - Pipeline Products by Mechanism of Action 126
AbbVie Inc. - Recent Pipeline Updates 131
AbbVie Inc. - Dormant Projects 160
AbbVie Inc. - Discontinued Pipeline Products 168
Discontinued Pipeline Product Profiles 168
AbbVie Inc. - Company Statement 173
AbbVie Inc. - Locations And Subsidiaries 174
Head Office 174
Other Locations & Subsidiaries 174
Appendix 182
Methodology 182
Coverage 182
Secondary Research 182
Primary Research 182
Expert Panel Validation 182
Contact Us 183
Disclaimer 183
List of Tables
AbbVie Inc., Key Information 10
AbbVie Inc., Key Facts 10
AbbVie Inc. - Pipeline by Indication, 2014 12
AbbVie Inc. - Pipeline by Stage of Development, 2014 17
AbbVie Inc. - Monotherapy Products in Pipeline, 2014 18
AbbVie Inc. - Combination Treatment Modalities in Pipeline, 2014 19
AbbVie Inc. - Partnered Products in Pipeline, 2014 20
AbbVie Inc. - Partnered Products/ Combination Treatment Modalities, 2014 21
AbbVie Inc. - Out-Licensed Products in Pipeline, 2014 23
AbbVie Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 24
AbbVie Inc. - Pre-Registration, 2014 25
AbbVie Inc. - Filing rejected/Withdrawn, 2014 26
AbbVie Inc. - Phase III, 2014 27
AbbVie Inc. - Phase II, 2014 29
AbbVie Inc. - Phase I, 2014 31
AbbVie Inc. - Preclinical, 2014 33
AbbVie Inc. - Discovery, 2014 35
AbbVie Inc. - Pipeline by Target, 2014 124
AbbVie Inc. - Pipeline by Route of Administration, 2014 128
AbbVie Inc. - Pipeline by Molecule Type, 2014 129
AbbVie Inc. - Pipeline Products by Mechanism of Action, 2014 130
AbbVie Inc. - Recent Pipeline Updates, 2014 135
AbbVie Inc. - Dormant Developmental Projects,2014 164
AbbVie Inc. - Discontinued Pipeline Products, 2014 172
AbbVie Inc., Other Locations 178
AbbVie Inc., Subsidiaries 179 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify